法国全国性真实世界研究:儿童与成人哮喘患者奥马珠单抗暴露与停药模式
成人停药前中位持续时间为51.2个月,儿童为53.7个月;暴露2年时哮喘住院率下降75%,口服糖皮质激素使用减少30%。哮喘控制下停药者中,成人1、2、3年后仍控制且未重启治疗的比例分别为70%、39%、24%,儿童更高。
要点
- 奥马珠单抗真实世界中位持续用药时间成人51.2个月,儿童53.7个月。
- 治疗2年时哮喘住院率下降75%,口服激素使用减少30%。
- 控制下停药后多数患者短期维持控制,儿童比例高于成人。
核心结论
- 奥马珠单抗在成人和儿童哮喘中真实世界持续用药时间长,暴露2年可大幅降低住院和口服激素使用。
- 哮喘控制下停药后,成人和儿童长期维持低医疗资源利用,儿童维持控制比例更高。
研究设计与样本
- 基于法国国家健康数据系统(SNDS)的全国性真实世界队列研究。
- 纳入2009至2019年起始奥马珠单抗治疗至少16周、年龄≥6岁的哮喘患者。
主要发现
- 停药前中位治疗持续时间为成人51.2个月(95%CI 49.3-53.4),儿童53.7个月(95%CI 50.6-56.4)。
- 暴露2年时,成人和儿童哮喘住院率下降75%,口服糖皮质激素使用减少30%。
- 控制下停药的成人中,1、2、3年后仍控制且未重启奥马珠单抗的比例分别为70%、39%、24%。
- 控制下停药的儿童中,上述比例分别为76%、44%、33%。
- 停药后2年随访期间医疗资源利用稳定,哮喘住院率在TSTOP前为0,2年时成人1.3%、儿童0.6%;口服激素使用在TSTOP前成人20.0%、儿童20.2%,2年时分别为33.3%和24.6%。
临床怎么用
- 真实世界中奥马珠单抗可持续使用较长时间,临床决策停药需综合评估控制状态。
- 哮喘控制下停药后仍应长期监测,因部分患者需重启治疗。
- 儿童停药后维持控制的比例高于成人,提示儿童停药策略可能更乐观。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This real-life study aimed to assess omalizumab treatment patterns in adult and paediatric asthma patients, and to describe asthma control and healthcare resource use (HCRU) at omalizumab initiation and discontinuation. METHODS: The French healthcare database system (Système National des Données de Santé (SNDS)) was used to identify asthma patients aged ≥6 years who initiated omalizumab for at least 16 weeks from 2009 to 2019. We examined omalizumab treatment patterns using dispensation records. RESULTS: We identified 16 750 adults and 2453 children initiating omalizumab. Median treatment persistence before discontinuation (TSTOP) was 51.2 (95% CI 49.3-53.4) months in adults and 53.7 (95% CI 50.6-56.4) months in children. At 2 years of omalizumab exposure, rate of hospitalisation for asthma decreased by 75% and use of oral corticosteroids (OCS) by 30%, in adults and children. Among adults who discontinued omalizumab while asthma was controlled, 70%, 39% and 24% remained controlled and did not resume omalizumab at 1, 2 and 3 years after discontinuation, respectively. These proportions were higher in children (76%, 44% and 33%, respectively). Over 2 years of follow-up after discontinuation, HCRU remained stable in adults and children, notably rate of hospitalisations for asthma (none before TSTOP, 1.3% and 0.6% at 2 years) and use of OCS (in adults and children, respectively: 20.0% and 20.2% before TSTOP, 33.3% and 24.6% at 2 years). CONCLUSION: This is the first large-scale study describing omalizumab real-life exposure patterns in adult and paediatric asthma patients in France with >10 years of follow-up. We showed the long-term maintenance of low HCRU in adults and children who discontinued omalizumab while asthma was controlled, notably for OCS use and hospitalisations for asthma.
引用
- Humbert M, Bourdin A, Taillé C, et al. Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patients. Eur Respir J. 2022. PMID: 35618272. doi:10.1183/13993003.03130-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。